A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
A formal single ascending and multiple dose pharmacokinetic (PK) trial of cannabidiol (CBD) oral solution was required to determine the safety and tolerability of CBD, the maximum tolerated dose, and to examine the effect of food on CBD PK parameters. This trial assessed the safety, tolerability and PK of CBD oral solution in healthy adult volunteers, as well as the effect of food on CBD PK parameters. The study consisted of three arms: single ascending dose (1500, 3000, 4500 or 6000 mg CBD [ n = 6 per group]/placebo [ n = 8; 2 per CBD dose group]), multiple dose (750 or 1500 mg CBD [ n = 9 per group]/placebo [ n = 6; 3 per CBD dose group] twice daily), and food effect (1500 mg CBD single dose [ n = 12]). All subjects completed all trial arms and were analyzed as planned. CBD was generally well tolerated. Diarrhea, nausea, headache, and somnolence were the most common adverse events (AEs) across all trial arms, with an increased incidence of some gastrointestinal and nervous system disorder AEs (most notably diarrhea and headache) apparent in subjects taking CBD compared with placebo. All AEs were of mild or moderate severity; none were severe or serious. There were no deaths or discontinuations in the trial. After single oral doses, CBD appeared rapidly in plasma; time to maximum plasma concentration ( t max ) was approximately 4–5 h. The major circulating metabolite was 7-carboxy-CBD, then parent CBD, 7-hydroxy-CBD (active metabolite), and 6-hydroxy-CBD (a relatively minor metabolite). Plasma exposure to CBD [maximum plasma concentration ( C max ) and area under the plasma concentration-time curve from time zero to time t (AUC t )] increased in a less than dose-proportional manner ( C max slope 0.73; AUC t slope 0.64). Oral clearance of CBD was high (1111–1909 L/h) and apparent volume of distribution was large (20,963–42,849 L). CBD reached steady state after approximately 2 days, with moderate accumulation (1.8- to 2.6-fold) after 750 and 1500 mg CBD twice daily. After 7 days, a twofold increase in CBD dose resulted in 1.6- and 1.9-fold increases in geometric mean C max and area under the plasma concentration-time curve over a dosing interval (AUC τ ), respectively. CBD elimination was multiphasic; the terminal elimination half-life was approximately 60 h after 750 and 1500 mg CBD twice daily; and effective half-life estimates ranged from 10 to 17 h. C max was 541.2 ng/mL and AUC τ was 3236 ng·h/mL after 1500 mg CBD twice daily. A high-fat meal increased CBD plasma exposure ( C max and AUC t ) by 4.85- and 4.2-fold, respectively; there was no effect of food on t max or terminal half-life. CBD was generally well tolerated. Most AEs were mild in severity; none were severe or serious. The safety and PK profile support twice-daily administration of CBD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome
Devinsky, O., Cross, J. H., Laux, L., Marsh, E., Miller, I., Nabbout, R., Scheffer, I. E., Thiele, E. A., & Wright, S. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611618 · Cited by 1,711
Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome
Devinsky, O., Patel, A. D., Cross, J. H., Villanueva, V., Wirrell, E. C., Privitera, M., Greenwood, S. M., Roberts, C., Checketts, D., VanLandingham, K. E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714631 · Cited by 1,015
Thiele, E. A., Marsh, E. D., French, J. A., Mazurkiewicz-Beldzinska, M., Benbadis, S. R., Joshi, C., Lyons, P. D., Taylor, A., Roberts, C., Sommerville, K., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30136-3 · Cited by 905
Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial
Devinsky, O., Marsh, E., Friedman, D., Thiele, E., Laux, L., Sullivan, J., Miller, I., Flamini, R., Wilfong, A., Filloux, F., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00379-8 · Cited by 900
Molecular Targets of Cannabidiol in Neurological Disorders
Ibeas Bih, C., Chen, T., Nunn, A. V. W., Bazelot, M., Dallas, M., & Whalley, B. J. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0377-3 · Cited by 578
Safety and side effects of cannabidiol, a Cannabis sativa constituent
Machado Bergamaschi, M., Helena Costa Queiroz, R., Waldo Zuardi, A., & Alexandre S. Crippa, J. (2011) · Current Drug Safety · doi:10.2174/157488611798280924 · Cited by 558
McPartland, J. M., Duncan, M., Di Marzo, V., & Pertwee, R. G. (2015) · British Journal of Pharmacology · doi:10.1111/bph.12944 · Cited by 521
Drug–drug interaction between clobazam and cannabidiol in children with refractory epilepsy
Geffrey, A. L., Pollack, S. F., Bruno, P. L., & Thiele, E. A. (2015) · Epilepsia · doi:10.1111/epi.13060 · Cited by 496
Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome
Devinsky, O., Patel, A. D., Thiele, E. A., Wong, M. H., Appleton, R., Harden, C. L., Greenwood, S., Morrison, G., Sommerville, K., On behalf of the GWPCARE1 Part A Study Group, et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005254 · Cited by 458
Self-citationInteractions between cannabidiol and commonly used antiepileptic drugs
Gaston, T. E., Bebin, E. M., Cutter, G. R., Liu, Y., Szaflarski, J. P., & Program, T. U. C. (2017) · Epilepsia · doi:10.1111/epi.13852 · Cited by 349
Stout, S. M., & Cimino, N. M. (2014) · Drug Metabolism Reviews · doi:10.3109/03602532.2013.849268 · Cited by 347
Jiang, R., Yamaori, S., Takeda, S., Yamamoto, I., & Watanabe, K. (2011) · Life Sciences · doi:10.1016/j.lfs.2011.05.018 · Cited by 322
Cannabinoids and Cytochrome P450 Interactions
Zendulka, O., Dovrtělová, G., Nosková, K., Turjap, M., Šulcová, A., Hanuš, L., & Juřica, J. (2016) · Current Drug Metabolism · doi:10.2174/1389200217666151210142051 · Cited by 291
Antipsychotic effect of cannabidiol.
Zuardi, A. W., Morais, S. L., Guimarães, F. S., & Mechoulam, R. (1995) · PubMed · Cited by 264
Absorption-Enhancing Effects of Bile Salts
Moghimipour, E., Ameri, A., & Handali, S. (2015) · Molecules · doi:10.3390/molecules200814451 · Cited by 255
Sylantyev, S., Jensen, T. P., Ross, R. A., & Rusakov, D. A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1211204110 · Cited by 213
Cannabidiol as a new treatment for drug‐resistant epilepsy in tuberous sclerosis complex
Hess, E. J., Moody, K. A., Geffrey, A. L., Pollack, S. F., Skirvin, L. A., Bruno, P. L., Paolini, J. L., & Thiele, E. A. (2016) · Epilepsia · doi:10.1111/epi.13499 · Cited by 190
Mazur, A., Lichti, C. F., Prather, P. L., Zielinska, A. K., Bratton, S. M., Gallus‐Zawada, A. E., Finel, M., Miller, G. P., Radominska-p, A., & Moran, J. H. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.026898 · Cited by 168
Henstridge, C. M., Balenga, N. A. B., Kargl, J., Andradas, C., Brown, A. J., Irving, A., Sanchez, C., & Waldhoer, M. (2011) · Molecular Endocrinology · doi:10.1210/me.2011-1197 · Cited by 158
Effective Half‐Life in Clinical Pharmacology
Boxenbaum, H., & Battle, M. (1995) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1995.tb04117.x · Cited by 106
Gidal, B. E., Clark, A. M., Anders, B., & Gilliam, F. (2017) · Epilepsy Research · doi:10.1016/j.eplepsyres.2016.10.020 · Cited by 26
Self-citation
Cited by
Hurd, Y. L., Spriggs, S., Alishayev, J., Winkel, G., Gurgov, K., Kudrich, C., Oprescu, A. M., & Salsitz, E. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.18101191 · Cited by 343
Cannabidiol: pharmacology and therapeutic targets
Britch, S. C., Babalonis, S., & Walsh, S. L. (2021) · Psychopharmacology · doi:10.1007/s00213-020-05712-8 · Cited by 307
“One study examined the pharmacokinetics of oral CBD in healthy adults; Taylor and colleagues found that a single administration of Epidiolex® had a Tmax range of 3–5 h (Taylor et al. 2018).”
BackgroundMethodInfluentialAdverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials
Chesney, E., Oliver, D., Green, A., Sovi, S., Wilson, J., Englund, A., Freeman, T. P., & McGuire, P. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0667-2 · Cited by 294
RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies
Traber, G. M., & Yu, A.-M. (2023) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.122.001234 · Cited by 291
Cannabidiol for Pain Treatment: Focus on Pharmacology and Mechanism of Action
Mlost, J., Bryk, M., & Starowicz, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228870 · Cited by 285
Metadata
- Authors
- Taylor, L., Gidal, B., Blakey, G., Tayo, B., & Morrison, G.
- Venue
- CNS Drugs
- Published
- 2018-10-30
- Volume
- 32
- Issue
- 11
- Pages
- 1053-1067
- ISSN
- 1172-7047 (ISSN-L)
- 1179-1934
- OpenAlex
- W2898687486
- Cited by
- 471
- References
- 21
- FWCI
- 19.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.